BR0314540A - Métodos para o tratamento de neurodegeneração - Google Patents
Métodos para o tratamento de neurodegeneraçãoInfo
- Publication number
- BR0314540A BR0314540A BR0314540-9A BR0314540A BR0314540A BR 0314540 A BR0314540 A BR 0314540A BR 0314540 A BR0314540 A BR 0314540A BR 0314540 A BR0314540 A BR 0314540A
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- neurodegeneration
- treatment
- disease
- alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"MéTODOS PARA O TRATAMENTO DE NEURODEGENERAçãO". Métodos de evitar ou de retardar a degeneração de neurónios. Também são divulgados métodos para o tratamento de doença de Alzheimer ou de doença de Parkinson através da administração de agonistas alfa 2 receptores B ou de alfa 2B/2C seletivos, aqui incorporados como referência.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41704902P | 2002-10-08 | 2002-10-08 | |
PCT/US2003/031809 WO2004032913A1 (en) | 2002-10-08 | 2003-10-07 | Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of neurodegeneration |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0314540A true BR0314540A (pt) | 2005-07-26 |
Family
ID=32093954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0314540-9A BR0314540A (pt) | 2002-10-08 | 2003-10-07 | Métodos para o tratamento de neurodegeneração |
Country Status (20)
Country | Link |
---|---|
US (1) | US20040138312A1 (pt) |
EP (1) | EP1549305B1 (pt) |
JP (2) | JP4724421B2 (pt) |
KR (1) | KR20050050124A (pt) |
CN (1) | CN100431536C (pt) |
AT (1) | ATE429216T1 (pt) |
AU (2) | AU2003282758A1 (pt) |
BR (1) | BR0314540A (pt) |
CA (1) | CA2501347A1 (pt) |
DE (1) | DE60327335D1 (pt) |
ES (1) | ES2322954T3 (pt) |
HK (1) | HK1081880A1 (pt) |
IL (1) | IL167849A (pt) |
MX (1) | MXPA05003664A (pt) |
NO (1) | NO20051663L (pt) |
NZ (1) | NZ539328A (pt) |
PL (1) | PL216373B1 (pt) |
RU (1) | RU2330649C2 (pt) |
WO (1) | WO2004032913A1 (pt) |
ZA (1) | ZA200502744B (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090304661A1 (en) * | 2006-03-16 | 2009-12-10 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Sceince | Method And Composition For Proctecting Neuronal Tissue From Damage Induced By Elevated Glutamate Levels |
WO2009052073A2 (en) * | 2007-10-18 | 2009-04-23 | Allergan, Inc. | Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists |
WO2009052072A1 (en) * | 2007-10-18 | 2009-04-23 | Allergan, Inc. | Treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione |
US20110160265A1 (en) * | 2007-10-18 | 2011-06-30 | Luhrs Lauren M B | Method of treating motor disorders with alpha-2b adrenergic receptor agonists |
ES2495099T3 (es) * | 2008-12-08 | 2014-09-16 | Allergan, Inc. | Compuestos de N-(1-fenil-2-ariletil)-4,5-dihidro-3H-pirrol-2-amina como moduladores selectivos de subtipo de los adrenoceptores alfa2B o alfa2B y alfa2C |
FI3562486T3 (fi) | 2016-12-31 | 2024-06-04 | Bioxcel Therapeutics Inc | Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa |
SG11202012772XA (en) | 2018-06-27 | 2021-01-28 | Bioxcel Therapeutics Inc | Film formulations containing dexmedetomidine and methods of producing them |
US20240024288A1 (en) | 2019-07-19 | 2024-01-25 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE795970A (fr) * | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
US4029792A (en) * | 1972-02-29 | 1977-06-14 | Pfizer Inc. | (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents |
US5210076A (en) * | 1988-09-13 | 1993-05-11 | Berliner David L | Methods of treating Parkinson's disease using melanin |
US6194415B1 (en) * | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
DE69823868T2 (de) * | 1997-12-04 | 2005-04-21 | Allergan Inc | Substituierte imidazole derivate mit agonistischähnlicher wirkung auf die alpha 2b oder 2b/2c adrenergischen rezeptoren |
US6329369B1 (en) * | 1997-12-04 | 2001-12-11 | Allergan Sales, Inc. | Methods of treating pain and other conditions |
US6841684B2 (en) * | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
US6313172B1 (en) * | 2000-04-13 | 2001-11-06 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
CA2402405C (en) * | 2000-07-14 | 2008-02-12 | Allergan Sales, Inc. | Compositions containing alpha-2-adrenergic agonist components |
WO2002058730A2 (en) * | 2000-11-01 | 2002-08-01 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
US7091232B2 (en) * | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
-
2003
- 2003-10-07 RU RU2005114504/14A patent/RU2330649C2/ru not_active IP Right Cessation
- 2003-10-07 WO PCT/US2003/031809 patent/WO2004032913A1/en active Application Filing
- 2003-10-07 PL PL376346A patent/PL216373B1/pl unknown
- 2003-10-07 CA CA002501347A patent/CA2501347A1/en not_active Abandoned
- 2003-10-07 JP JP2004543495A patent/JP4724421B2/ja not_active Expired - Fee Related
- 2003-10-07 ES ES03774642T patent/ES2322954T3/es not_active Expired - Lifetime
- 2003-10-07 EP EP03774642A patent/EP1549305B1/en not_active Expired - Lifetime
- 2003-10-07 AT AT03774642T patent/ATE429216T1/de not_active IP Right Cessation
- 2003-10-07 MX MXPA05003664A patent/MXPA05003664A/es active IP Right Grant
- 2003-10-07 KR KR1020057006114A patent/KR20050050124A/ko active IP Right Grant
- 2003-10-07 US US10/680,879 patent/US20040138312A1/en not_active Abandoned
- 2003-10-07 AU AU2003282758A patent/AU2003282758A1/en not_active Abandoned
- 2003-10-07 NZ NZ539328A patent/NZ539328A/en not_active IP Right Cessation
- 2003-10-07 BR BR0314540-9A patent/BR0314540A/pt not_active Application Discontinuation
- 2003-10-07 DE DE60327335T patent/DE60327335D1/de not_active Expired - Lifetime
- 2003-10-07 CN CNB200380101115XA patent/CN100431536C/zh not_active Expired - Fee Related
-
2005
- 2005-04-04 IL IL167849A patent/IL167849A/en active IP Right Grant
- 2005-04-04 NO NO20051663A patent/NO20051663L/no unknown
- 2005-04-05 ZA ZA200502744A patent/ZA200502744B/en unknown
-
2006
- 2006-03-31 HK HK06104018.4A patent/HK1081880A1/xx not_active IP Right Cessation
-
2009
- 2009-11-20 AU AU2009238370A patent/AU2009238370B2/en not_active Ceased
-
2010
- 2010-12-03 JP JP2010270724A patent/JP2011057700A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN100431536C (zh) | 2008-11-12 |
RU2330649C2 (ru) | 2008-08-10 |
PL216373B1 (pl) | 2014-03-31 |
HK1081880A1 (en) | 2006-05-26 |
AU2009238370A1 (en) | 2009-12-17 |
KR20050050124A (ko) | 2005-05-27 |
NZ539328A (en) | 2007-01-26 |
NO20051663L (no) | 2005-05-31 |
AU2003282758A1 (en) | 2004-05-04 |
ATE429216T1 (de) | 2009-05-15 |
AU2009238370B2 (en) | 2011-07-21 |
RU2005114504A (ru) | 2005-10-27 |
MXPA05003664A (es) | 2005-06-08 |
ES2322954T3 (es) | 2009-07-02 |
JP2011057700A (ja) | 2011-03-24 |
WO2004032913A1 (en) | 2004-04-22 |
PL376346A1 (en) | 2005-12-27 |
EP1549305B1 (en) | 2009-04-22 |
JP4724421B2 (ja) | 2011-07-13 |
JP2006504739A (ja) | 2006-02-09 |
CA2501347A1 (en) | 2004-04-22 |
CN1703213A (zh) | 2005-11-30 |
EP1549305A1 (en) | 2005-07-06 |
US20040138312A1 (en) | 2004-07-15 |
ZA200502744B (en) | 2006-02-22 |
IL167849A (en) | 2011-04-28 |
DE60327335D1 (de) | 2009-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20051663L (no) | Fremgangsmater for behandling av neurodegenerasjon | |
TW200600087A (en) | Methods and compositions for treating amyloid-related diseases | |
BR0207526A (pt) | Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral | |
MXPA05014166A (es) | Metodos y composiciones para tratar enfermedades relacionadas con amiloide. | |
DK1377589T3 (da) | Oxazolyl-pyrazolderivater som kinaseinhibitorer | |
BRPI0606466A2 (pt) | amilina e agonistas de amilina para o tratamento de doenças e distúrbios psiquiátricos | |
DK1196397T3 (da) | Metabotrope glutamatreceptorantagonister og anvendelse deraf til behandling af sygdomme i centralnervesystemet | |
DK1525177T3 (da) | Substituerede 1,3-diphenylprop-2-en-1-on-derivater, fremstilling og anvendelse deraf | |
DOP2002000429A (es) | Imidazotriazinas | |
WO2003080582A3 (de) | Fredericamycin-derivate | |
BRPI0407662A (pt) | derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas | |
BRPI0506970A (pt) | derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior | |
TW200528117A (en) | Methods and reagents for the treatment of proliferative diseases | |
WO2007016338A3 (en) | Use of chk2 kinase inhibitors for cancer treatment | |
BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
DK1578740T3 (da) | 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet | |
CY1109666T1 (el) | Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας | |
NO20044530L (no) | Fremgangsmate for behandling av kognitive forstyrrelser | |
BRPI0409562A (pt) | tratamento de condições envolvendo placas amilóides | |
WO2003072572A8 (en) | Beta3-adrenergic receptor agonists | |
DK1223930T3 (da) | Behandling af dyskinesi | |
BR0314541A (pt) | Tratamento de demência e doença de parkinson | |
BR0308753A (pt) | Método para produzir pseudo-ilhotas | |
ATE293107T1 (de) | Luminacine analoge und deren verwendung | |
UA43140A (uk) | Спосіб надвисокочастотної мікрохвильової терапії при вегетативних порушеннях |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |